Search

Your search keyword '"Tabernero E"' showing total 4 results
Start Over Author "Tabernero E" Topic coronavirus infections
4 results on '"Tabernero E"'

1. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.

Author

Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S, Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvão T, García-Clemente M, García-García JM, Gualano G, Gullón-Blanco JA, Inwentarz S, Ippolito G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Muñoz-Torrico M, Njungfiyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabriá J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A, Tabernero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF, Sotgiu G, Ong CWM, and Goletti D

Subjects
Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2, Tuberculosis epidemiology, Continuity of Patient Care trends, Coronavirus Infections epidemiology, Facilities and Services Utilization trends, Global Health trends, Pneumonia, Viral epidemiology, Tuberculosis therapy
Abstract

Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019. Resources are needed to ensure tuberculosis care continuity during the pandemic.

Published
2020
Full Text
View/download PDF

2. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.

Author

Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, Luiza De Souza-Galvão M, Dominguez-Castellano A, Dourmane S, Fréchet Jachym M, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Marín Royo M, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Silva DR, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Tabernero E, Tambyah PA, Tiberi S, Torre A, Visca D, Zabaleta Murguiondo M, Sotgiu G, and Migliori GB

Subjects
Adult, Aged, Antitubercular Agents therapeutic use, Antiviral Agents therapeutic use, Azithromycin therapeutic use, Betacoronavirus, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques, Cohort Studies, Coinfection, Coronavirus Infections diagnosis, Coronavirus Infections drug therapy, Drug Combinations, Emigrants and Immigrants, Female, Humans, Hydroxychloroquine therapeutic use, Lopinavir therapeutic use, Lung diagnostic imaging, Male, Middle Aged, Mortality, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral drug therapy, Ritonavir therapeutic use, SARS-CoV-2, Tomography, X-Ray Computed, Tuberculosis complications, Tuberculosis diagnosis, Tuberculosis drug therapy, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary drug therapy, COVID-19 Drug Treatment, Coronavirus Infections complications, Pneumonia, Viral complications, Tuberculosis, Pulmonary complications
Abstract

Competing Interests: Conflict of interest: M. Tadolini has nothing to disclose. Conflict of interest: L.R. Codecasa has nothing to disclose. Conflict of interest: J-M. García-García has nothing to disclose. Conflict of interest: F-X. Blanc has nothing to disclose. Conflict of interest: S. Borisov has nothing to disclose. Conflict of interest: J-W. Alffenaar has nothing to disclose. Conflict of interest: C. Andréjak has nothing to disclose. Conflict of interest: P. Bachez has nothing to disclose. Conflict of interest: P-A. Bart has nothing to disclose. Conflict of interest: E. Belilovski has nothing to disclose. Conflict of interest: J. Cardoso-Landivar has nothing to disclose. Conflict of interest: R. Centis has nothing to disclose. Conflict of interest: L. D'Ambrosio has nothing to disclose. Conflict of interest: M-L. De Souza-Galvão has nothing to disclose. Conflict of interest: A. Dominguez-Castellano has nothing to disclose. Conflict of interest: S. Dourmane has nothing to disclose. Conflict of interest: M. Fréchet Jachym has nothing to disclose. Conflict of interest: A. Froissart has nothing to disclose. Conflict of interest: V. Giacomet has nothing to disclose. Conflict of interest: D. Goletti has nothing to disclose. Conflict of interest: S. Grard has nothing to disclose. Conflict of interest: G. Gualano has nothing to disclose. Conflict of interest: A. Izadifar has nothing to disclose. Conflict of interest: D. Le Du has nothing to disclose. Conflict of interest: M. Marín Royo has nothing to disclose. Conflict of interest: J. Mazza-Stalder has nothing to disclose. Conflict of interest: I. Motta has nothing to disclose. Conflict of interest: C.W.M. Ong has nothing to disclose. Conflict of interest: F. Palmieri has nothing to disclose. Conflict of interest: F. Rivière has nothing to disclose. Conflict of interest: T. Rodrigo has nothing to disclose. Conflict of interest: D.R. Silva has nothing to disclose. Conflict of interest: A. Sánchez-Montalvá has nothing to disclose. Conflict of interest: M. Saporiti has nothing to disclose. Conflict of interest: P. Scarpellini has nothing to disclose. Conflict of interest: F. Schlemmer has nothing to disclose. Conflict of interest: A. Spanevello has nothing to disclose. Conflict of interest: E. Sumarokova has nothing to disclose. Conflict of interest: E. Tabernero has nothing to disclose. Conflict of interest: P.A. Tambyah has nothing to disclose. Conflict of interest: S. Tiberi has nothing to disclose. Conflict of interest: A. Torre has nothing to disclose. Conflict of interest: D. Visca has nothing to disclose. Conflict of interest: M. Zabaleta Murguiondo has nothing to disclose. Conflict of interest: G. Sotgiu has nothing to disclose. Conflict of interest: G.B. Migliori has nothing to disclose.

Published
2020
Full Text
View/download PDF

3. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts.

Author

Motta I, Centis R, D'Ambrosio L, García-García JM, Goletti D, Gualano G, Lipani F, Palmieri F, Sánchez-Montalvá A, Pontali E, Sotgiu G, Spanevello A, Stochino C, Tabernero E, Tadolini M, van den Boom M, Villa S, Visca D, and Migliori GB

Subjects
Adult, Age Distribution, Aged, Aged, 80 and over, Antimalarials therapeutic use, Antitubercular Agents therapeutic use, Betacoronavirus, COVID-19, Cohort Studies, Coronavirus Infections complications, Coronavirus Infections therapy, Female, Humans, Hydroxychloroquine therapeutic use, Length of Stay, Male, Middle Aged, Noninvasive Ventilation, Oxygen Inhalation Therapy, Pandemics, Pneumonia, Viral complications, Pneumonia, Viral therapy, Retrospective Studies, SARS-CoV-2, Tuberculosis, Pulmonary complications, Tuberculosis, Pulmonary drug therapy, Coinfection mortality, Coronavirus Infections mortality, Pneumonia, Viral mortality, Transients and Migrants statistics & numerical data, Tuberculosis, Pulmonary mortality
Abstract

Little is known about the relationship between the COVID-19 and tuberculosis (TB). The aim of this study is to describe a group of patients who died with TB (active disease or sequelae) and COVID-19 in two cohorts. Data from 49 consecutive cases in 8 countries (cohort A) and 20 hospitalised patients with TB and COVID-19 (cohort B) were analysed and patients who died were described. Demographic and clinical variables were retrospectively collected, including co-morbidities and risk factors for TB and COVID-19 mortality. Overall, 8 out of 69 (11.6%) patients died, 7 from cohort A (14.3%) and one from cohort B (5%). Out of 69 patients 43 were migrants, 26/49 (53.1%) in cohort A and 17/20 (85.0%) in cohort B. Migrants: (1) were younger than natives; in cohort A the median (IQR) age was 40 (27-49) VS. 66 (46-70) years, whereas in cohort B 37 (27-46) VS. 48 (47-60) years; (2) had a lower mortality rate than natives (1/43, 2.3% versus 7/26, 26.9%; p-value: 0.002); (3) had fewer co-morbidities than natives (23/43, 53.5% versus 5/26-19.2%) natives; p-value: 0.005). The study findings show that: (1) mortality is likely to occur in elderly patients with co-morbidities; (2) TB might not be a major determinant of mortality and (3) migrants had lower mortality, probably because of their younger age and lower number of co-morbidities. However, in settings where advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, higher mortality rates can be expected in young individuals., (Copyright © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2020
Full Text
View/download PDF

4. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Author

Elena Sumarokova, Gina Gualano, Evgeny Belilovski, Armine Izadifar, Eva Tabernero, Pierre Bachez, Alessandro Torre, Maria Luiza de Souza-Galvão, François-Xavier Blanc, Claire Andrejak, Mathilde Fréchet Jachym, Denise Rossato Silva, Paolo Scarpellini, Margarita Marín Royo, Dina Visca, Ángel Domínguez-Castellano, Teresa Rodrigo, Antoine Froissart, Damien Le Dû, Giovanni Sotgiu, Antonio Spanevello, Pierre-Alexandre Bart, Simon Tiberi, Miguel Zabaleta Murguiondo, Frédéric Schlemmer, Marina Tadolini, Rosella Centis, Matteo Saporiti, Sergey Borisov, Giovanni Battista Migliori, Vania Giacomet, Delia Goletti, Frédéric Rivière, Ilaria Motta, Samir Dourmane, Soazic Grard, José Cardoso-Landivar, José-María García-García, Jesica Mazza-Stalder, Fabrizio Palmieri, Luigi Codecasa, Catherine W.M. Ong, Adrián Sánchez-Montalvá, Lia D'Ambrosio, Jan-Willem C. Alffenaar, Paul A. Tambyah, Tadolini M., Codecasa L.R., Garcia-Garcia J.-M., Blanc F.-X., Borisov S., Alffenaar J.-W., Andrejak C., Bachez P., Bart P.-A., Belilovski E., Cardoso-Landivar J., Centis R., D'Ambrosio L., De Souza-Galvao M.-L., Dominguez-Castellano A., Dourmane S., Jachym M.F., Froissart A., Giacomet V., Goletti D., Grard S., Gualano G., Izadifar A., Le Du D., Royo M.M., Mazza-Stalder J., Motta I., Min Ong C.W., Palmieri F., Riviere F., Rodrigo T., Silva D.R., Sanchez-Montalva A., Saporiti M., Scarpellini P., Schlemmer F., Spanevello A., Sumarokova E., Tabernero E., Tambyah P.A., Tiberi S., Torre A., Visca D., Murguiondo M.Z., Sotgiu G., Migliori G.B., Centre hospitalier universitaire de Nantes (CHU Nantes), University Medical Center Groningen [Groningen] (UMCG), CHU Amiens-Picardie, Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Henri Mondor, Centre Hospitalier Intercommunal de Créteil (CHIC), Istituto Nazionale di Malattie Infettive 'Lazzaro Spallanzani' (INMI), Service de pneumologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Hôpital Raymond Poincaré [AP-HP], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Maturation des proteines, destinée cellulaire et thérapeutique (PROMTI), Département Biologie des Génomes (DBG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Aristotle University of Thessaloniki, [Tadolini,m] Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. [Codecasa,LR, Saporiti,M] TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy. [García-García,JM, Rodrigo,T]Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain. [Blanc,FX] Centre Hospitalier Universitaire, Nantes, France. [Borisov,S, Belilovski,E, Sumarokova,E] Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation. [Alffenaar,JW] The University of Sydney, Sydney Pharmacy School, Sydney, Australia. [Alffenaar,JW] Westmead Hospital, Sydney, Australia. [Alffenaar,JW] Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia. [Andréjak,C] Service de Pneumologie CHU AMIENS PICARDIE, France AND UR Université de Picardie Jules Verne, Amiens, France. [Bachez,P] Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium. [Bart,PA] Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland. [Cardoso-Landivar,J] Servicio Neumología, Vall D´Hebron University Hospital, Barcelona, Spain. [Centis,R] Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy. [D'Ambrosio,L] Public Health Consulting Group, Lugano, Switzerland. [Dominguez-Castellano,A] Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain. [Dourmane,S] Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France. [Fréchet Jachym,M, Le Du,D] Centre Hospitalier de Bligny, Briis Sous Forges, France. [Froissart,A] Service de Médecine interne, CHI de Créteil, Créteil, France. [Giacomet,V]20Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy. [Goletti,D] Translational Research Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy. [Grard,S] Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France. [Gualano,G, Palmieri,F] Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy. [Izadifar,A] Hôpital Européen de Paris La Roseraie, Aubervilliers, France. [Marín Royo,M] Servicio Neumología, Hospital General Universitario de Castellón, Castelló, Spain. [Mazza-Stalder,J] Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. [Motta,I] Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia. [Ong,CWM, Tambyah,PA] Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. [Ong,CWM, Tambyah,PA] Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore. [Rivière,F] Hôpital d'Instruction des Armées (HIA) Percy, Clamart, France. [Silva,DR] Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, Brazil. [Sánchez-Montalvá,A]Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d'Hebron University Hospital, Barcelona, Spain. [Sánchez-Montalvá,A] Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain. [Sánchez-Montalvá,A] Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain. [Scarpellini,P] Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy. [Schlemmer,F] Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France. [Spanevello,A, Visca,D] Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy. [Spanevello,A, Visca,D] Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy. [Tabernero,E] Servicio Neumología, Hospital de Cruces, Bilbao, Spain. [Tiberi,S] Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. [Tiberi,S] Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK. [Torre,A] Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy. [Zabaleta Murguiondo,M] Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Sotgiu,G] Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. [Migliori,GB] Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy., and CHU Henri Mondor [Créteil]

Subjects
Male, Pediatrics, Adult, Aged, Antitubercular Agents/therapeutic use, Antiviral Agents/therapeutic use, Azithromycin/therapeutic use, Betacoronavirus, Clinical Laboratory Techniques, Cohort Studies, Coinfection, Coronavirus Infections/complications, Coronavirus Infections/diagnosis, Coronavirus Infections/drug therapy, Drug Combinations, Emigrants and Immigrants, Female, Humans, Hydroxychloroquine/therapeutic use, Lopinavir/therapeutic use, Lung/diagnostic imaging, Middle Aged, Mortality, Pandemics, Pneumonia, Viral/complications, Pneumonia, Viral/diagnosis, Pneumonia, Viral/drug therapy, Ritonavir/therapeutic use, Tomography, X-Ray Computed, Tuberculosis/complications, Tuberculosis/diagnosis, Tuberculosis/drug therapy, Tuberculosis, Pulmonary/complications, Tuberculosis, Pulmonary/diagnosis, Tuberculosis, Pulmonary/drug therapy, [SDV]Life Sciences [q-bio], viruses, Antitubercular Agents, Azithromycin, Clinical Laboratory Technique, Lopinavir, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Sequelae, Antitubercular Agent, 0302 clinical medicine, COVID-19 Testing, Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography [Medical Subject Headings], Drug Combination, 030212 general & internal medicine, Viral, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques [Medical Subject Headings], Lung, Tomography, ComputingMilieux_MISCELLANEOUS, Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Vital Statistics::Mortality [Medical Subject Headings], virus diseases, Pulmonary, respiratory system, X-Ray Computed, Impactos en la salud, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography [Medical Subject Headings], Cohort, Coronavirus Infections, medicine.drug, Cohort study, Human, Hydroxychloroquine, Impacts on health, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, Tuberculosi, Infecciones por coronavirus, Estudios de cohortes, Pneumonia, Viral, Antiviral Agents, Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis [Medical Subject Headings], 03 medical and health sciences, Tuberculosis diagnosis, medicine, Research Letter, Tuberculosis, Pulmonary, Secuelas, Ritonavir, Antiviral Agent, Pandemia, Betacoronaviru, Pandemic, business.industry, Coronavirus Infection, SARS-CoV-2, COVID-19, Emigrants and Immigrant, Pneumonia, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents::Antitubercular Agents [Medical Subject Headings], medicine.disease, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], COVID-19 Drug Treatment, Coronavirus, 030228 respiratory system, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Cohort Studie, business
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has attracted interest because of its global rapid spread, clinical severity, high mortality rate, and capacity to overwhelm healthcare systems [1, 2]. SARS-CoV-2 transmission occurs mainly through droplets, although surface contamination contributes and debate continues on aerosol transmission [3–5].

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results